What MIRAVA THERAPEUTICS LTD does

MiRAVA Therapeutics Ltd is a pre-clinical stage biotechnology company founded in 2023 and headquartered in Edinburgh, Scotland, that develops microRNA-based therapeutics for chronic wound care. The company's sole lead asset, miRHeal, is a microRNA mimic therapy designed to promote vascularisation and accelerate wound healing in chronic ulcers, particularly diabetic foot ulcers. The therapy is delivered as a non-invasive topical application using microRNA mimics dissolved in a hydrogel applied directly to the wound. Efficacy has been demonstrated across five successful pre-clinical studies covering four distinct models: cellular assays, a mouse model, 3D skin models, and diabetic patient skin explants. The company has one patent pending covering the miRHeal technology and its underlying research has been cited 86 times in scientific literature.

The company's technology platform is built on proprietary microRNA mimic chemistry paired with a hydrogel delivery vehicle, enabling localized, non-invasive treatment. MiRAVA is co-founded by Dr Vlad Miscianinov (CEO), whose background is in molecular biology and gene therapies and who previously managed a healthtech business through fundraising, and Dr Andrea Caporali (CSO), an Associate Professor in Cardiovascular Science at the University of Edinburgh and a widely published expert in microRNA in vascular disease. The 1-10 employee team is focused exclusively on advancing miRHeal toward clinical development.

MiRAVA has not yet commercialized any product and has no disclosed revenue. Its intended business model is pharmaceutical therapeutic sales of miRHeal following successful clinical development and regulatory approval, with commercialization to be executed through strategic pharmaceutical or medical device partners rather than through an in-house sales force. The company is actively exploring partnership opportunities, has not disclosed any funding rounds to date, and operates as a private limited company domiciled in Scotland, United Kingdom.

Name

MIRAVA THERAPEUTICS LTD

Legal name

MIRAVA THERAPEUTICS LTD

Website

https://miravatherapeutics.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

MiRAVA Therapeutics Ltd is a pre-clinical Edinburgh-based biotechnology company developing miRHeal, a microRNA-based topical wound healing therapy targeting chronic ulcers such as diabetic foot ulcers, with commercialization intended through future strategic pharmaceutical partnerships.

Ownership category

akta.pro rank

Product category

Wound Care Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Wound Care & Ulcer Management (HLAKACAN)

akta.pro secondary industry

Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis) (HLAAAGAJ)

Keywords

• Wound care therapeutics
• MicroRNA therapy
• Diabetic foot ulcers
• Chronic wound healing
• Topical hydrogel therapy

Headquarters

HQ city

Edinburgh

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Therapeutic Sales: As a therapeutic development company, MiRAVA intends to generate revenue through the sale of its miRHeal wound care product. The company is in pre-clinical stage and has not yet commercialized its product. Revenue generation will depend on successful clinical development, regulatory approval, and market entry for treatment of chronic wounds such as diabetic foot ulcers.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

MiRAVA Therapeutics develops miRHeal, a microRNA-based advanced wound healing therapy designed as a microRNA mimic that promotes vascularisation and expedites wound healing. The therapy is delivered non-invasively as microRNA mimics dissolved in a topical hydrogel applied directly to chronic wounds such as diabetic foot ulcers. The company is in pre-clinical stage, has completed five successful pre-clinical studies across four distinct model types, and is actively seeking strategic pharmaceutical partners for clinical development and commercialisation.

Product overview

MiRAVA Therapeutics is a single-product company developing miRHeal, a microRNA-based advanced wound healing therapeutic. The company focuses exclusively on this one product, which is designed to heal chronic ulcers through a non-invasive topical application of microRNA mimics in a hydrogel formulation. The therapy has been tested across four preclinical models and is specifically targeted at diabetic foot ulcers and similar non-healing wounds.

Differentiator

Problem solved

Functional benefit

Products and services

• miRHeal miRHeal is a microRNA-based advanced wound healing therapy designed as a microRNA mimic that promotes vascularisation and expedites wound healing. It is delivered non-invasively as microRNA mimics dissolved in a topical hydrogel applied directly to chronic wounds such as diabetic foot ulcers. Currently in pre-clinical development for patients with chronic non-healing wounds.

Quantifiable outcome

• Demonstrated efficacy across four distinct pre-clinical models including cellular assays, mouse model, 3D skin models, and diabetic patient skin explants
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Strategic Partners (Exploration)coreStrategic or Co-development PartnerMiRAVA Therapeutics is actively exploring strategic partnership opportunities for the development and commercialization of miRHeal. The company is seeking partners with capabilities in pharmaceutical development, clinical trials, regulatory affairs, and commercial distribution to advance the microRNA-based wound healing therapy through to market approval.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Organogenesis: Commercial-stage wound care company developing advanced wound healing products including skin substitutes and active wound dressings for chronic ulcers including diabetic foot ulcers - the most direct commercial comparable for MiRAVA's target indication.
• Viridian Therapeutics (formerly miRagen Therapeutics): Originally founded as a microRNA-based therapeutics company developing microRNA mimics and antimiRs for cardiovascular and other diseases. Closest comparable to MiRAVA's microRNA mimic technology platform, though now focused on thyroid eye disease.

Broad incumbents

• MiMedx: Commercial-stage regenerative medicine company specializing in placental tissue allografts for wound healing and surgical applications, directly competing in chronic wound care including diabetic foot ulcers.
• Smith & Nephew: Global medical device company with substantial Advanced Wound Management division offering a broad portfolio of wound dressings, NPWT systems, and bioactive skin substitutes for chronic wounds including diabetic foot ulcers.
• Alnylam Pharmaceuticals: Leading commercial-stage RNA therapeutics company pioneering RNAi-based drugs. Comparable as an RNA-based therapeutic platform developer, though focused on siRNA/liver-targeted applications rather than topical wound care.
• ConvaTec: Major wound care company offering advanced wound dressings, skin substitutes (e.g., Apligraf), and antimicrobial products targeting chronic wounds, diabetic foot ulcers, and post-surgical wounds.
• Coloplast: Danish medical device company with established wound care division offering advanced dressings and skin substitutes for chronic wounds, including diabetic foot ulcers, in hospital and homecare settings.
• Integra LifeSciences: Diversified medical device company with significant wound care and regenerative tissue portfolio including dermal regeneration templates and skin substitutes used in chronic wound treatment.

Peers

• RegeneRx Biopharmaceuticals:

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MIRAVA THERAPEUTICS LTD